1887
Rapid communication Open Access
Like 0

Abstract

The BNT162b2 mRNA COVID-19 vaccine showed high efficacy in clinical trials but observational data from populations not included in trials are needed. We describe immunogenicity 21 days post-dose 1 among 514 Israeli healthcare workers by age, ethnicity, sex and prior COVID-19 infection. Immunogenicity was similar by ethnicity and sex but decreased with age. Those with prior infection had antibody titres one magnitude order higher than naïve individuals regardless of the presence of detectable IgG antibodies pre-vaccination.

Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2021.26.6.2100096
2021-02-11
2021-03-01
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2021.26.6.2100096
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/26/6/eurosurv-26-6-1.html?itemId=/content/10.2807/1560-7917.ES.2021.26.6.2100096&mimeType=html&fmt=ahah

References

  1. World Health Organization (WHO). WHO Coronavirus Disease (COVID-19) Dashboard. Geneva: WHO. [Accessed: 25 Jan 2021]. Available from: https://covid19.who.int/
  2. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403-16.  https://doi.org/10.1056/NEJMoa2035389  PMID: 33378609 
  3. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603-15.  https://doi.org/10.1056/NEJMoa2034577  PMID: 33301246 
  4. Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2021;396(10267):1979-93.  https://doi.org/10.1016/S0140-6736(20)32466-1  PMID: 33220855 
  5. Aldridge RW, Lewer D, Katikireddi SV, Mathur R, Pathak N, Burns R, et al. Black, Asian and Minority Ethnic groups in England are at increased risk of death from COVID-19: indirect standardisation of NHS mortality data. Wellcome Open Res. 2020;5:88.  https://doi.org/10.12688/wellcomeopenres.15922.2  PMID: 32613083 
  6. Izurieta HS, Graham DJ, Jiao Y, Hu M, Lu Y, Wu Y, et al. Natural history of COVID-19: Risk factors for hospitalizations and deaths among> 26 million US Medicare beneficiaries. J Infect Dis. 2020 Dec 16;jiaa767. doi:  https://doi.org/10.1093/infdis/jiaa767 . Online ahead of print.
  7. Ministry of Health of Israel. [Coronavirus in Israel – general situation]. Jerusalem: Ministry of Health. [Accessed: 25 Jan 2021]. Hebrew. Available from: https://datadashboard.health.gov.il/COVID-19/general
  8. Turbett SE, Anahtar M, Dighe AS, Garcia Beltran W, Miller T, Scott H, et al. Evaluation of Three Commercial SARS-CoV-2 Serologic Assays and Their Performance in Two-Test Algorithms. J Clin Microbiol. 2020;59(1):59.  https://doi.org/10.1128/JCM.01892-20  PMID: 33020186 
  9. Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020;586(7830):589-93.  https://doi.org/10.1038/s41586-020-2639-4  PMID: 32785213 
  10. Lumley SF, Wei J, O’Donnell D, Stoesser NE, Matthews PC, Howarth A, et al. The duration, dynamics and determinants of SARS-CoV-2 antibody responses in individual healthcare workers. Clin Infect Dis. 2021;2021(Jan):6. PMID: 33400782 
  11. Gaebler C, Wang Z, Lorenzi JCC, Muecksch F, Finkin S, Tokuyama M, et al. Evolution of Antibody Immunity to SARS-CoV-2. bioRxiv. 2020;2020.11.03.367391. PMID: 33173867 
  12. Hall V, Foulkes S, Charlett A, Atti A, Monk EJM, Simmons R, et al. Do antibody positive healthcare workers have lower SARS-CoV-2 2 infection rates than antibody negative healthcare workers? Large 3 multi-centre prospective cohort study (the SIREN study), England: 4 June to November 2020. medRxiv.  https://doi.org/10.1101/2021.01.13.21249642 
  13. Centers for Disease Control and Prevention (CDC). Frequently Asked Questions about COVID-19 Vaccination. Atlanta: CDC. [Accessed: 25 Jan 2021]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/faq.html
/content/10.2807/1560-7917.ES.2021.26.6.2100096
Loading

Data & Media loading...

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error